Rallybio Corp (RLYB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.19 (+0.17%), Market cap $0.08B, 52-week low–high $0.29 ~ $14.66.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to
Financial statements, price targets, institutional (13F) holdings and related news for Rallybio Corp are updated in real time on BlackAll Trade.
Rallybio Corp trades at $17.19 (+0.17%). Real-time quotes and charts are available on BlackAll Trade.
Rallybio Corp has a market cap of about $0.08B.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its